Compare ODC & CRVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ODC | CRVS |
|---|---|---|
| Founded | 1941 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Miscellaneous manufacturing industries | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 1994 | 2016 |
| Metric | ODC | CRVS |
|---|---|---|
| Price | $76.62 | $12.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $30.17 |
| AVG Volume (30 Days) | 33.2K | ★ 1.4M |
| Earning Date | 06-04-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.13% | N/A |
| EPS Growth | ★ 50.45 | 48.04 |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $485,572,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $46.19 | ★ N/A |
| Revenue Growth | ★ 10.97 | N/A |
| 52 Week Low | $45.61 | $3.38 |
| 52 Week High | $79.20 | $26.95 |
| Indicator | ODC | CRVS |
|---|---|---|
| Relative Strength Index (RSI) | 61.30 | 34.30 |
| Support Level | $70.67 | $6.65 |
| Resistance Level | N/A | $19.21 |
| Average True Range (ATR) | 2.02 | 1.08 |
| MACD | 0.06 | -0.28 |
| Stochastic Oscillator | 66.45 | 2.89 |
Oil-Dri Corp of America develops, manufactures, and markets sorbent products made predominantly from clay. Its absorbent offerings, which draw liquid up, include cat litter, floor products, toxin control substances for livestock, and agricultural chemical carriers. The company has two segments based on the different characteristics of two primary customer groups, namely the Retail and Wholesale Products Group, which derives maximum revenue, and the Business-to-Business Products Group. The company's products are sold under various brands such as Cat's Pride, Jonny Cat, Amlan, Agsorb, Verge, Pure-Flo, and Ultra-Clear.
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.